Incyte announced that the EC has approved Opzelura (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical… read more.
AstraZeneca withdrew its application for the use of Imfinzi (durvalumab) in combination with BCG in the treatment of high-risk non-muscle invasive bladder cancer (NMIBC), a type of cancer… read more.
Exercise finds improvements in pain and function may fall short of what patients would notice in daily life, but more studies are needed to make firm conclusions, a… read more.
Mild COVID-19 can cause severe and long-lasting eye problems, according to a study from Linköping University, Sweden. The study also explains why it has been difficult for sufferers… read more.
Sanofi withdrew its application for the use of Dupixent (dupilumab) in the treatment of adults with moderate-to-severe bullous pemphigoid, an autoimmune skin disease causing widespread itching and blisters… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation in the EU for the medicinal product Icotyde (icotrokinra), intended for… read more.
A new oral antiviral drug candidate administered either before or after direct contact or airborne exposure to canine distemper virus, which causes measles-like disease in ferrets, blocks transmission… read more.
Boehringer Ingelheim announced that the European Commission (EC) has granted marketing authorization for Jascayd (nerandomilast) for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with… read more.
Gilead Sciences announced that the CHMP of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy (sacituzumab govitecan-hziy) in combination with… read more.
Metabolic dysfunction‑associated fatty liver disease (MAFLD) is a leading chronic liver disease in China, yet primary care capacity remains limited. To address this, the first national Guidelines for Diagnosis… read more.
Many countries are using too many powerful and inappropriate antibiotics, fuelling antibiotic resistance concerns, while millions lack access to the specific drugs they need. That is according to… read more.
Roche announced that the CHMP has recommended the approval of Susvimo (ranibizumab injection) 100 mg/mL for the treatment of neovascular age-related macular degeneration (nAMD). Susvimo is intended for… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
